Pal-AHK vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —